Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies-Reference-Cited by-同舟云学术

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

Published:2017-12-14 Issue:1 Volume:178 Page:132-139
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Gordon K.B.¹,Blauvelt A.²,Foley P.³⁴,Song M.⁵,Wasfi Y.⁵,Randazzo B.⁵,Shen Y.K.⁵,You Y.⁵,Griffiths C.E.M.⁶

Affiliation:

1. Medical College of Wisconsin Milwaukee WI U.S.A.

2. Oregon Medical Research Center Portland OR U.S.A.

3. The University of Melbourne St Vincent's Hospital Melbourne Australia

4. Skin & Cancer Foundation Inc. Carlton Victoria Australia

5. Janssen Research & Development LLC Spring House PA U.S.A.

6. The Dermatology Centre Salford Royal Hospital The University of Manchester Manchester Academic Health Science Centre Manchester U.K.

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.16008

Reference32 articles.

1. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

2. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

3. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

4. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

5. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial;Acta Dermato-Venereologica;2024-09-05

2. Psoriasis Comorbidities and Their Treatment Impact;Dermatologic Clinics;2024-07

3. The Intersection of the Pathogenic Processes Underlying Psoriasis and the Comorbid Condition of Obesity;Life;2024-06-07

4. Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20‐week interim analysis of a postmarketing surveillance study;The Journal of Dermatology;2024-05-15

5. Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities;Expert Review of Clinical Pharmacology;2024-04-02